Abstract
The prolonged recovery phase of cell-mediated immunity after allogeneic hematopoietic stem cell transplantation (SCT) brings serious and often fatal risks from opportunistic reactivation or acquisition of common viruses.1 Post-transplant immunodeficiency particularly involves defective T-cell function, and it is now established that adoptive transfer of viral-specific T cells can prevent and treat viral complications.2,3,4,5 In this issue, Gerdemann and colleagues describe a technique to generate clinical-grade virus-specific T-cell lines targeting seven viruses that commonly cause morbidity and mortality after SCT.6
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
